TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05177211
Drug: Fedratinib Pill
Normalized name: fedratinib Pill
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be given Fedratinib at a dose of 400 mg PO once daily (4-100 mg capsules). Fedratinib can be given at any time during the day, but patients are advised to take the dose at the same approximate time every day.
Study: NCT04477759
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 4 weeks following the initiation of radiation treatment up to 1 year from radiation fraction 1.
Study: NCT06554574
Drug: LTG-305
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Single-Ascending dose cohorts; Part B: Multiple-ascending dose cohorts
Study: NCT05488678
Drug: Ceftibuten
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral dose
Study: NCT06210646
Drug: Citicoline 2000
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The citicoline arm consists of 400 patients who received 2000 mg citicoline once daily for 12 months, and an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
Study: NCT06210646
Drug: citocoline 1000
Normalized name: citicoline 1000 MG
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo arm consists of 400 patients who received a citicoline 1000 mg once daily for 12 months, an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
Study: NCT05393986
Drug: CT048 Autologous Injection (CT048)
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 3 times CT048 Autologous Injection infusion
Study: NCT06061094
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib 600mg QD plus Chemotherapy
Study: NCT06061094
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ponatinib 45 mg QD plus chemotherapy
Study: NCT06061094
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with molecular failure or intermediate response receive one cycle Blinatumomab before SCT; Patients with molecular CR randomized to the experimental arm receive 3 cycles Blinatumomab + chemotherapy
Study: NCT06151743
Drug: three cycles (toripalimab + cetuximab + platinum)
Normalized name: three-lobe sage extract
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab 250 mg/m2 i.v. qw (first loading dose 400 mg/m2) for nine doses; Toripalimab 240 mg/m2 i.v. d1, q21d, three cycles; Cisplatin 25 mg/m2 i.v. d1-3, q21d, three cycles or Carboplatin AUC 5 i.v. d1, q21d, three cycles (patients with cisplatin contraindications or renal impairment after cisplatin use).
Study: NCT06026527
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg Magnesium sulphate in 93-95 ml Normal Saline ( making a total of 100 ml solution )will be infused intravenously over 20-30 minutes in the participants allocated to M group starting from the moment of induction of anaesthesia
Study: NCT06753825
Drug: flunarizine
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: flunarizine oral treatment
Study: NCT04760782
Drug: Abaloparatide
Normalized name: Abaloparatide
DrugBank: Abaloparatide (DB05084)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abaloparatide 80 mcg by subcutaneous, self-administered injection once per day (8 weeks)
Study: NCT05031520
Drug: Isovue
Normalized name: Isovue-370
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCTA requires intravenous catheter placement and the administration of iodinated contrast media (Isovue).
Study: NCT05031520
Drug: Nitroglycerin
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication to promote coronary vasodilation during the CCTA may be administered immediately prior to CCTA to optimize image quality
Study: NCT05031520
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication to promote heart rate reduction during the CCTA may be administered immediately prior to CCTA to optimize image quality
Study: NCT05827523
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75mg/m2 after interval cytoreductive surgery
Study: NCT06122610
Drug: 64Cu-Dotatate
Normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care administration of radioactive drug for PET/CT
Study: NCT06122610
Drug: 177Lu-Dotatate
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care administration of radioactive drug for PET/CT and SPECT/CT
Study: NCT05736744
Drug: MgSO4
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.
Study: NCT05736744
Drug: Cis-Atracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.
Study: NCT06755099
Drug: Botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: The patient will be placed in gynecological position. Subsequently, the patient will be anesthetized with propofol bolus, a total of 270 mg IV sterilization of valval area with antiseptic solution then digital examination to assess the spasm of intriotus and vaginal walls under lowest possible doses then increasing the doses to allow for intra vaginal injection of Botox under full sedation. Pacik technique will be adopted for Botox Injection in the vagina .~. One vial of frozen Botox 100 U will be diluted with 2 mL saline, without foaming or shaking the vial, giving a concentration of 2.5 U/0.05 mL . Using a small sized speculum and after bending the needle to 30° to facilitate injection into sub mucosal area,1 mL (50 U) of Botox will be injected into the right bulbocavernosus then into the left side .
Study: NCT05550207
Drug: AXS-07 (meloxicam-rizatriptan)
Normalized name: AX
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AXS-07 tablets, taken orally for the acute treatment of migraine
Study: NCT04703101
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04701307
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04676529
Drug: PXS-5505
Normalized name: PXS-5505
DrugBank: PXS-5505 (DB17510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.
Study: NCT05744921
Drug: Pozelimab
Normalized name: Pozelimab
DrugBank: Pozelimab (DB15218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC) every 4 weeks (Q4W)
Study: NCT05744921
Drug: Cemdisiran
Normalized name: Cemdisiran
DrugBank: Cemdisiran (DB16121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC Q4W
Study: NCT05226442
Drug: Argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban is a synthetic, univalent DTI, that directly binds to the catalytic thrombin binding site exerting its effects
Study: NCT06510491
Drug: Epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific antibody, via subcutaneous (under the skin) injection per protocol.
Study: NCT04903314
Drug: Xcopri
Normalized name: Xcopri
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Xcopri will be administered orally not to exceed 400mg/day adult equivalent
Study: NCT05422794
Drug: BET Bromodomain Inhibitor ZEN-3694
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05422794
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT06118281
Drug: Ziltivekimab
Normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziltivekimab will be adminsitered subcutaneously as an initial loading dose of Dose 1 followed by a maintenance dose of Dose 2 once- monthly.
Study: NCT05226442
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin produces its major anticoagulant effect by inactivating thrombin and activated factor X (factor Xa) through an antithrombin (AT)-dependent mechanism.
Study: NCT06775236
Drug: SYS6010 jnjection
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker
Study: NCT06775236
Drug: monotherapy chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of monotherapy chemotherapy (Eribulin, Capecitabine, Gemcitabine, Vinorelbine, or Taxanes.)
Study: NCT05370235
Drug: Afamelanotide
Normalized name: Afamelanotide
DrugBank: Afamelanotide (DB04931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
Study: NCT05983965
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment: On day 1 and day 15 of the first cycle, and day 1 of all following cycles, the subject will have office visit with physical exam, vital signs, and lab tests. The subject will take tazemetostat twice a day by mouth continuously as an outpatient. If continuing on the treatment for more than 6 cycles, visits change to every 3 months.
Study: NCT05322954
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg orally followed by 25 mg or 50 mg orally
Study: NCT04836559
Drug: JNJ-40411813
Normalized name: JNJ-40411813
DrugBank: JNJ-40411813 (DB12059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-40411813 will be administered orally.
Study: NCT05674526
Drug: Cetuximab - Dose Escalation
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 500mg/m2 administered on Days 29 and 43
Study: NCT06370715
Drug: Insulin Lispro-aabc
Normalized name: insulin lispro-aabc
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT06370715
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT06781567
Drug: HG146
Normalized name: Hydralazine Hydrochloride
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
Study: NCT06781957
Drug: Gonadotropins Subcutaneos
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropins s.c. single dose
Study: NCT06768671
Drug: Sonelokimab
Normalized name: Sonelokimab
DrugBank: Sonelokimab (DB18843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label
Study: NCT04031677
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * High grade LPS: ADM 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m2 Q3 weeks~* LMS: ADM 75 mg/m2 + DTIC 1g/m2 Q3 weeks~Note: the recommended dose of Doxorubicin (or Epirubicin) can be modified according to national/institutional guidelines, given that the minimal threshold must be Doxorubicin 60 mg/m2 per cycle (or the equivalent Epirubicin 95 mg/m2 per cycle); the recommended dose of Ifosfamide can be modified according to national/institutional guidelines, given that the minimal threshold must be 7.5 g/m2 per cycle; the recommended dose of Dacarbazine can be modified according to national/institutional guidelines, given that the minimal threshold must be 900 mg/m2 per cycle. The schedule of administration of above chemotherapies can be modified according to national/institutional guidelines provided that the minimal threshold of doses, and the treatment periods with chemotherapies remain the same.
Study: NCT06022029
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous administration of 350 mg
Study: NCT06780410
Drug: Bempedoic Acid Tablet
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once daily, oral
Study: NCT06594393
Drug: TCP-25 gel
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical gel
Study: NCT06504160
Drug: Clobetasol Ointment
Normalized name: clobetasol Topical Ointment
DrugBank: Clobetasol (DB11750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will apply clobetasol ointment 0.05% alongside the study product in non-sensitive body areas (e.g., arms, legs, torso) for the first two weeks of the trial. It will be applied twice daily to lesional skin and selected sampling areas from Baseline to Week 2. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.
Study: NCT06504160
Drug: Fluocinonide Ointment
Normalized name: Fluocinonide Ointment
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants with a past intolerance to clobetasol or who become too sensitive to clobetasol in the initial two-week cotreatment period will apply fluocinonide ointment 0.05% as an alternative. In these cases, fluocinonide ointment 0.05% will be applied alongside the study product in non-sensitive body areas (e.g., arms, legs, torso) for the first two weeks of the trial. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.
Study: NCT06594393
Drug: Vehicle (placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel
Study: NCT05607446
Drug: TQC3564 tablets, montelukast sodium tablets
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention drugs are TQC3564 tablets combined with montelukast sodium tablets. TQC3564 is a CRTH2 antagonist, montelukast sodium is Leukotriene receptor antagonist.
Study: NCT05607446
Drug: Placebo tablets, montelukast sodium tablets
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention drugs are placebo combined with montelukast sodium tablets. Montelukast sodium is Leukotriene receptor antagonist.
Study: NCT06764771
Drug: BMS-986488
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT06764771
Drug: Adagrasib
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06764771
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06764771
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06763666
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06763666
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06763666
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT06763666
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04643158
Drug: Run-in medications (ICS-LABA combination)
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care.
Study: NCT06182839
Drug: Canagliflozin 300Mg Tab
Normalized name: CANAGLIFLOZIN 300MG TAB
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will get 1 pill of Canagliflozin 300 mg daily for one year.
Study: NCT06078696
Drug: Siplizumab
Normalized name: Siplizumab
DrugBank: Siplizumab (DB06371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication with diphenhydramine 50 mg PO is to be given 1 hour prior to siplizumab infusion. Premedication with hydrocortisone succinate 100 mg IV infused over 30 minutes and acetaminophen 650 mg PO are to be given at least 30 minutes prior to siplizumab infusion. Siplizumab 4.8 mg/kg total is given on Day -14 and 0.6mg/kg is given on days -6, -1, 0, and +1. It will be given as an IV infusion over 1 hour.
Study: NCT06593821
Drug: Botulinum toxin
Normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 50 U of botulinum toxin, 25 U in each muscle, was injected
Study: NCT06078696
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesna is to be given starting 1 hour prior to cyclophosphamide at the same dose (50 mg/kg) as a continuous infusion over 24 hours.
Study: NCT06078696
Drug: Sirolimus Oral Tablet
Normalized name: sirolimus Oral Tablet
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus will be given orally with a loading dose of 12 mg, then followed by 4 mg orally daily. Dosage will be adjusted to a therapeutic target of 10 - 15ng/ml in first 3 months post transplant and 3-10 after 3 months. Sirolimus should be started on day +5. It will be continued until at least day 180. Sirolimus can be tapered or continued according to the treating physician discretion and the presence of absence of GVHD and/or degree of donor chimerism. Sirolimus should be continued if donor chimerism is less than 50% to prevent graft loss.
Study: NCT06078696
Drug: Rituximab or Biosimilar
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (375 mg/m2/dose) will be administered on Days -14 and -6. In those subjects receiving ongoing renal replacement therapy, rituximab should be administered several hours after hemodialysis. The first rituximab solution for infusion should be administered intravenously at an initial rate of 50 milligrams/hour (mg/hr). The rate may be escalated by 50mg/hr every 30 minutes to a maximum of 400 mg/hr. Subsequent infusions may be started at 100 milligrams/hour (mg/hr) and titrated by 100 mg/hr every 30 minutes to a maximum of 400mg/hr if the subject tolerated the first infusion.
Study: NCT05064449
Drug: Soticlestat
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat tablets.
Study: NCT06436833
Drug: 2-Liter polyethylene glycol plus elobixibat
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Elobixibat 10 mg, one day before colonoscopy at 8 a.m. Take Polyethylene glycol 1 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 1 Liter, at day of colonoscopy at 5 a.m.
Study: NCT06436833
Drug: 4-Liter polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Polyethylene glycol 2 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 2 Liter, at day of colonoscopy at 5 a.m.
Study: NCT04934722
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
Study: NCT05688436
Drug: Diroximel Fumarate
Normalized name: Diroximel fumarate
DrugBank: Diroximel fumarate (DB14783)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05688436
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05688436
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05064449
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution.
Study: NCT05688436
Drug: Ozanimod
Normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as specified in the treatment arm.